1. Home
  2. CUE vs RFM Comparison

CUE vs RFM Comparison

Compare CUE & RFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • RFM
  • Stock Information
  • Founded
  • CUE 2014
  • RFM 2020
  • Country
  • CUE United States
  • RFM United States
  • Employees
  • CUE N/A
  • RFM N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • RFM Finance/Investors Services
  • Sector
  • CUE Health Care
  • RFM Finance
  • Exchange
  • CUE Nasdaq
  • RFM Nasdaq
  • Market Cap
  • CUE 91.9M
  • RFM 92.3M
  • IPO Year
  • CUE 2018
  • RFM N/A
  • Fundamental
  • Price
  • CUE $1.28
  • RFM $15.70
  • Analyst Decision
  • CUE Strong Buy
  • RFM
  • Analyst Count
  • CUE 5
  • RFM 0
  • Target Price
  • CUE $5.00
  • RFM N/A
  • AVG Volume (30 Days)
  • CUE 283.2K
  • RFM 20.7K
  • Earning Date
  • CUE 03-10-2025
  • RFM 01-01-0001
  • Dividend Yield
  • CUE N/A
  • RFM 9.74%
  • EPS Growth
  • CUE N/A
  • RFM N/A
  • EPS
  • CUE N/A
  • RFM N/A
  • Revenue
  • CUE $9,532,000.00
  • RFM N/A
  • Revenue This Year
  • CUE $73.11
  • RFM N/A
  • Revenue Next Year
  • CUE $11.02
  • RFM N/A
  • P/E Ratio
  • CUE N/A
  • RFM N/A
  • Revenue Growth
  • CUE 149.53
  • RFM N/A
  • 52 Week Low
  • CUE $0.45
  • RFM $12.89
  • 52 Week High
  • CUE $2.58
  • RFM $16.41
  • Technical
  • Relative Strength Index (RSI)
  • CUE 46.30
  • RFM 65.66
  • Support Level
  • CUE $1.20
  • RFM $15.24
  • Resistance Level
  • CUE $1.50
  • RFM $15.60
  • Average True Range (ATR)
  • CUE 0.12
  • RFM 0.07
  • MACD
  • CUE -0.02
  • RFM 0.05
  • Stochastic Oscillator
  • CUE 38.30
  • RFM 99.98

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

About RFM RiverNorth Flexible Municipal Income Fund Inc.

RiverNorth Flexible Municipal Income Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.

Share on Social Networks: